Posted 5/30/2017 8:57 PM (GMT 0)
Tall Allen,
I was offered a Clinical Trial in the Spring of 2016 at OHSU involving Ipilimumab (Yervoy), but declined, in part, due to the longer distance from where I live, and wanting to see what UCSF had to say, first. At UCSF I later obtained Provenge as a next treatment since I was still pretty asymptomatic, and was also offered a Provenge-followed-by-Ipilimumab Clinical Trial. After some consideration, I declined the Ipilimumab Trial, due to my concerns about the potential side effects of the CTLA-4 inhibitor, and what can happen when it "releases the hounds" of the body's killer T cells, hopefully against the cancer cells, but, all too often, also against various parts of the body, with significant side effects often requiring some rescue interventions. (I was also having some intermittent episodes of Atrial Fibrillation with Rapid Ventricular Response at the time, and some disorientation due to macular degeneration in one eye, which was, and is still, being treated with injections of Avastin (bevacizumab) into that eyeball.)
(In hindsight, I'm just as glad I did decline the "Ipi" Trial at that time. Shortly thereafter, the results of a Phase III Trial of "Ipi" vs. Placebo showed no benefit for Overall Survival (OS), and 9 men died in the Trial in the "Ipi' arm due to treatment related Adverse Effects of the "Ipi".)
Reference: http://ascopubs.org/doi/abs/10.1200/jco.2016.69.1584
Charles